IDEAS home Printed from https://ideas.repec.org/f/psc810.html
   My authors  Follow this author

Mark Sculpher

Personal Details

First Name:Mark
Middle Name:
Last Name:Sculpher
Suffix:
RePEc Short-ID:psc810
[This author has chosen not to make the email address public]
https://www.york.ac.uk/che/staff/research/mark-sculpher/

Research output

as
Jump to: Working papers Articles Chapters Books

Working papers

  1. Fan Yang & Colin Angus & Ana Duarte & Duncan Gillespie & Mark Sculpher & Simon Walker & Susan Griffin, 2021. "Comparing smoking cessation to screening and brief intervention for alcohol in distributional cost effectiveness analysis to explore the sensitivity of results to socioeconomic inequalities characteri," Working Papers 184cherp, Centre for Health Economics, University of York.
  2. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
  3. Walker, S. & Griffin, Susan & Asaria, Miqdad & Tsuchyia, Aki & Sculpher, Mark, 2019. "Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision-makers," LSE Research Online Documents on Economics 100541, London School of Economics and Political Science, LSE Library.
  4. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
  5. Asaria, Miqdad & Walker, Simon & Palmer, Stephen & Gale, Chris P & Shah, Anoop D & Abrams, Keith R & Crowther, Michael & Manca, Andrea & Timmis, Adam & Hemingway, Harry & Sculpher, Mark, 2016. "Using electronic health records to predict costs and outcomes in stable coronary artery disease," LSE Research Online Documents on Economics 101257, London School of Economics and Political Science, LSE Library.
  6. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
  7. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
  8. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.
  9. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.
  10. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
  11. Karl Claxton & Mark Sculpher & Stuart Carroll, 2011. "Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS," Working Papers 060cherp, Centre for Health Economics, University of York.
  12. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
  13. Richard Edlin & Christopher McCabe & Jeff Round & Judy Wright & Karl Claxton & Mark Sculpher & Richard Cookson, 2010. "Understanding Harris’ understanding of CEA: is cost effective resource allocation undone?," Working Papers 1005, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
  14. Louise Longworth & Laura Bojke & Jonathan Tosh & Mark Sculpher, 2009. "MRC-NICE scoping project: identifying the national institute for health and clinical excellence’s methodological research priorities and an initial set of priorities," Working Papers 051cherp, Centre for Health Economics, University of York.
  15. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
  16. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.
  17. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
  18. Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs, 2000. "Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling," Working Papers 179chedp, Centre for Health Economics, University of York.
  19. M Sculpher & A Gafni, 1999. "Recognizing Preference Diversity: The Use of Preference Sub-Groups in Cost-Effectiveness Analysis," Centre for Health Economics and Policy Analysis Working Paper Series 1999-01, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  20. M Sculpher & B O'Brien, 1999. "Income Effects of Reduced Health and Health Effects of Reduced Income: Implications for Health State Valuation," Centre for Health Economics and Policy Analysis Working Paper Series 1999-02, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  21. B O'Brien & M Sculpher, 1999. "Building Uncertainty into Cost-Effectiveness Rankings: Portfolio Risk-Return Trade-Offs and Implications for Decision Rules," Centre for Health Economics and Policy Analysis Working Paper Series 1999-05, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  22. Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.
  23. Andrew Briggs & Diana Gibb & Mark Sculpher & Sandra MacDonagh & Tony Ades, 1996. "Antenatal testing for HIV Infection: Developing a Model for Economic Evaluation," Discussion Papers 14, Brunel University, Health Economics Research Group.
  24. Mark Sculpher & Michael Drummond & Martin Buxton, 1995. "Economic Evaluation in Health Care Research and Development: Undertake it Early and Often," Discussion Papers 12, Brunel University, Health Economics Research Group.

Articles

  1. Naomi Kate Gibbs & Jessica Ochalek & Indra Bahadur Napit & Dilip Shrestha & Pedro Saramago Goncalves & Richard J Lilford & Mark Sculpher, 2025. "Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in Nepal," PLOS ONE, Public Library of Science, vol. 20(2), pages 1-12, February.
  2. Beth Woods & Alfredo Palacios & Mark Sculpher, 2025. "A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence," PharmacoEconomics, Springer, vol. 43(4), pages 363-373, April.
  3. Beth Woods & Ben Kearns & Laetitia Schmitt & Dina Jankovic & Claire Rothery & Sue Harnan & Jean Hamilton & Alison Scope & Shijie Ren & Laura Bojke & Mark Wilcox & William Hope & Colm Leonard & Philip , 2025. "Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England," Applied Health Economics and Health Policy, Springer, vol. 23(1), pages 5-17, January.
  4. Charlton, Victoria & DiStefano, Michael & Mitchell, Polly & Morrell, Liz & Rand, Leah & Badano, Gabriele & Baker, Rachel & Calnan, Michael & Chalkidou, Kalipso & Culyer, Anthony & Howdon, Daniel & Hug, 2024. "We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment," Health Economics, Policy and Law, Cambridge University Press, vol. 19(2), pages 153-173, April.
  5. Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
  6. Nancy J. Devlin & Tianxin Pan & Mark Sculpher & Mark Jit & Elly Stolk & Donna Rowen & Barend Hout & Richard Norman, 2023. "Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?," PharmacoEconomics, Springer, vol. 41(10), pages 1165-1174, October.
  7. Simon Walker & Aimee Fox & James Altunkaya & Tim Colbourn & Mike Drummond & Susan Griffin & Nils Gutacker & Paul Revill & Mark Sculpher, 2022. "Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making," Medical Decision Making, , vol. 42(1), pages 17-27, January.
  8. Sakshi Mohan & Paul Revill & Stefano Malvolti & Melissa Malhame & Mark Sculpher & Paul M Kaye, 2022. "Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 16(6), pages 1-17, June.
  9. Fan Yang & Kenneth R. Katumba & Bram Roudijk & Zhihao Yang & Paul Revill & Susan Griffin & Perez N. Ochanda & Mohammed Lamorde & Giulia Greco & Janet Seeley & Mark Sculpher, 2022. "Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol," PharmacoEconomics, Springer, vol. 40(3), pages 309-321, March.
  10. Marta O. Soares & Mark J. Sculpher & Karl Claxton, 2021. "Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.†by Sampson, Firth, and Towse," Medical Decision Making, , vol. 41(3), pages 258-260, April.
  11. Ana Duarte & Simon Walker & Andrew Metry & Ruth Wong & Jasmina Panovska-Griffiths & Mark Sculpher, 2021. "Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies," PharmacoEconomics, Springer, vol. 39(8), pages 879-887, August.
  12. Beth Woods & Aimée Fox & Mark Sculpher & Karl Claxton, 2021. "Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems," Health Economics, John Wiley & Sons, Ltd., vol. 30(11), pages 2649-2666, November.
  13. Marta O. Soares & Mark J. Sculpher & Karl Claxton, 2020. "Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts," Medical Decision Making, , vol. 40(4), pages 448-459, May.
  14. Susan Griffin & Simon Walker & Mark Sculpher, 2020. "Distributional cost effectiveness analysis of West Yorkshire low emission zone policies," Health Economics, John Wiley & Sons, Ltd., vol. 29(5), pages 567-579, May.
  15. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
  16. Simon Walker & Susan Griffin & Miqdad Asaria & Aki Tsuchiya & Mark Sculpher, 2019. "Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 577-590, October.
  17. Joanna Emerson & Ari Panzer & Joshua T Cohen & Kalipso Chalkidou & Yot Teerawattananon & Mark Sculpher & Thomas Wilkinson & Damian Walker & Peter J Neumann & David D Kim, 2019. "Adherence to the iDSI reference case among published cost-per-DALY averted studies," PLOS ONE, Public Library of Science, vol. 14(5), pages 1-13, May.
  18. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
  19. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
  20. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
  21. Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher, 2018. "Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 28-40, February.
  22. Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher, 2018. "Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment," Medical Decision Making, , vol. 38(4), pages 495-508, May.
  23. Claire Rothery & Karl Claxton & Stephen Palmer & David Epstein & Rosanna Tarricone & Mark Sculpher, 2017. "Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 109-123, February.
  24. Rita Faria & Simon Walker & Sophie Whyte & Simon Dixon & Stephen Palmer & Mark Sculpher, 2017. "How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants," Medical Decision Making, , vol. 37(2), pages 148-161, February.
  25. Beth Woods & Andrea Manca & Helen Weatherly & Pedro Saramago & Eleftherios Sideris & Christina Giannopoulou & Stephen Rice & Mark Corbett & Andrew Vickers & Matthew Bowes & Hugh MacPherson & Mark Scul, 2017. "Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-18, March.
  26. Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher, 2016. "Should the Lambda (λ) Remain Silent?," PharmacoEconomics, Springer, vol. 34(4), pages 323-329, April.
  27. Karl Claxton & Mark Sculpher & Stephen Palmer & Anthony J Culyer, 2015. "Causes For Concern: Is Nice Failing To Uphold Its Responsibilities To All Nhs Patients?," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 1-7, January.
  28. M. Barbieri & H. Weatherly & R. Ara & H. Basarir & M. Sculpher & R. Adams & H. Ahmed & C. Coles & T. Guerrero-Urbano & C. Nutting & M. Powell, 2014. "What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer," Applied Health Economics and Health Policy, Springer, vol. 12(5), pages 497-510, October.
  29. Manuel A. Espinoza & Andrea Manca & Karl Claxton & Mark J. Sculpher, 2014. "The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis," Medical Decision Making, , vol. 34(8), pages 951-964, November.
  30. Eldon Spackman & Stewart Richmond & Mark Sculpher & Martin Bland & Stephen Brealey & Rhian Gabe & Ann Hopton & Ada Keding & Harriet Lansdown & Sara Perren & David Torgerson & Ian Watt & Hugh MacPherso, 2014. "Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
  31. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
  32. Mark Sculpher, 2013. "Methods Development for Health Technology Assessment," Medical Decision Making, , vol. 33(3), pages 313-315, April.
  33. Andrew H. Briggs & Milton C. Weinstein & Elisabeth A. L. Fenwick & Jonathan Karnon & Mark J. Sculpher & A. David Paltiel, 2012. "Model Parameter Estimation and Uncertainty Analysis," Medical Decision Making, , vol. 32(5), pages 722-732, September.
  34. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.
  35. Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott, 2012. "Golimumab for the Treatment of Psoriatic Arthritis," PharmacoEconomics, Springer, vol. 30(4), pages 257-270, April.
  36. Vilija R. Joyce & Paul G. Barnett & Adam Chow & Ahmed M. Bayoumi & Susan C. Griffin & Huiying Sun & Mark Holodniy & Sheldon T. Brown & Tassos C. Kyriakides & D. William Cameron & Mike Youle & Mark Scu, 2012. "Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV," Medical Decision Making, , vol. 32(1), pages 70-82, January.
  37. Patrick W. Sullivan & Julia F. Slejko & Mark J. Sculpher & Vahram Ghushchyan, 2011. "Catalogue of EQ-5D Scores for the United Kingdom," Medical Decision Making, , vol. 31(6), pages 800-804, November.
  38. Susan C. Griffin & Karl P. Claxton & Stephen J. Palmer & Mark J. Sculpher, 2011. "Dangerous omissions: the consequences of ignoring decision uncertainty," Health Economics, John Wiley & Sons, Ltd., vol. 20(2), pages 212-224, February.
  39. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136, October.
  40. Rachel Elliott & Helen Weatherly & Neil Hawkins & Gillian Cranny & Duncan Chambers & Lindsey Myers & Alison Eastwood & Mark Sculpher, 2010. "An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 57-66, February.
  41. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
  42. Laura Bojke & Karl Claxton & Mark J. Sculpher & Stephen Palmer, 2008. "Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration," Medical Decision Making, , vol. 28(1), pages 33-43, January.
  43. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2008. "The Value of Implementation and the Value of Information: Combined and Uneven Development," Medical Decision Making, , vol. 28(1), pages 21-32, January.
  44. Diego Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher, 2007. "Recombinant Erythropoietin for Chemotherapy-Related Anaemia," PharmacoEconomics, Springer, vol. 25(3), pages 223-237, March.
  45. David M. Epstein & Zaid Chalabi & Karl Claxton & Mark Sculpher, 2007. "Efficiency, Equity, and Budgetary Policies," Medical Decision Making, , vol. 27(2), pages 128-137, March.
  46. Laura Bojke & Edward Hornby & Mark Sculpher, 2007. "A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD," PharmacoEconomics, Springer, vol. 25(10), pages 829-841, October.
  47. Andrea Manca & Paul C. Lambert & Mark Sculpher & Nigel Rice, 2007. "Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling," Medical Decision Making, , vol. 27(4), pages 471-490, July.
  48. Hege Urdahl & Andrea Manca & Mark Sculpher, 2006. "Assessing Generalisability in Model-Based Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 24(12), pages 1181-1197, December.
  49. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.
  50. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4, January.
  51. Elisabeth Fenwick & Steve Palmer & Karl Claxton & Mark Sculpher & Keith Abrams & Alex Sutton, 2006. "An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery," Medical Decision Making, , vol. 26(5), pages 480-496, September.
  52. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
  53. Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.
  54. Neil Hawkins & David Epstein & Michael Drummond & Jennifer Wilby & Anita Kainth & David Chadwick & Mark Sculpher, 2005. "Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model," Medical Decision Making, , vol. 25(5), pages 493-510, September.
  55. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.
  56. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347, April.
  57. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496, May.
  58. Louise Longworth & Martin Buxton & Mark Sculpher & David Smith, 2005. "Estimating utility data from clinical indicators for patients with stable angina," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 347-353, December.
  59. Andrew Briggs & Martin Buxton & Mike Drummond & Ron Goeree & Mark J. Sculpher & Andrew R. Willan, 2004. "Unfinished Symphony: A Tribute to the Life and Career of Bernie O’Brien (1959–2004)," Medical Decision Making, , vol. 24(5), pages 538-544, October.
  60. Mark Sculpher & Amiram Gafni, 2002. "Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 653-654, October.
  61. Sculpher, Mark & Gafni, Amiram & Watt, Ian, 2002. "Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions," Social Science & Medicine, Elsevier, vol. 54(9), pages 1369-1377, May.
  62. Mark Sculpher & Amiram Gafni, 2001. "Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 10(4), pages 317-324, June.
  63. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.
  64. Mark Sculpher & Michael Palmer & Anne Heyes, 2000. "Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy," PharmacoEconomics, Springer, vol. 17(4), pages 361-370, April.
  65. Mark J. Sculpher & Bernie J. O'Brien, 2000. "Income Effects of Reduced Health and Health Effects of Reduced Income:," Medical Decision Making, , vol. 20(2), pages 207-215, April.
  66. Mark Sculpher, 1998. "The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia," Health Economics, John Wiley & Sons, Ltd., vol. 7(2), pages 129-142, March.
  67. Andrew Briggs & Mark Sculpher, 1995. "Sensitivity analysis in economic evaluation: A review of published studies," Health Economics, John Wiley & Sons, Ltd., vol. 4(5), pages 355-371, September.

Chapters

  1. Jessica Ochalek & Gerald Manthalu & Dominic Nkhoma & Finn McGuire & Alexandra Rollinger & Paul Revill & Mark Sculpher & Karl Claxton & Peter Berman, 2020. "Supporting the Development of Health Benefits Packages (HBPs): Principles and Initial Assessment for Malawi," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 10, pages 265-273, World Scientific Publishing Co. Pte. Ltd..
  2. Paul Revill & Jessica Ochalek & James Lomas & Ryota Nakamura & Beth Woods & Alexandra Rollinger & Marc Suhrcke & Mark Sculpher & Karl Claxton & Peter Berman, 2020. "Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 3, pages 75-97, World Scientific Publishing Co. Pte. Ltd..
  3. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.

Books

  1. Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), 2020. "Global Health Economics:Shaping Health Policy in Low- and Middle-Income Countries," World Scientific Books, World Scientific Publishing Co. Pte. Ltd., number 11045.
  2. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629, Decembrie.
  3. Clive Pritchard;Martin Sculpher, 2000. "Productivity Costs: Principles and Practice in Economic Evaluation," Monograph 000464, Office of Health Economics.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Rankings

This author is among the top 5% authors according to these criteria:
  1. Number of Distinct Works
  2. Euclidian citation score

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 8 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (5) 2008-02-16 2010-04-17 2014-05-24 2015-03-13 2016-10-02. Author is listed
  2. NEP-ORE: Operations Research (2) 2019-07-29 2021-09-27
  3. NEP-IAS: Insurance Economics (1) 2019-06-17
  4. NEP-ISF: Islamic Finance (1) 2021-09-27
  5. NEP-PKE: Post Keynesian Economics (1) 2014-05-24

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Mark Sculpher should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.